Killing a fly with a sledgehammer: Atezolizumab exposure in real‐world lung cancer patients

AbstractAtezolizumab is an anti‐PDL1 approved for treating lung cancer. A threshold of 6 μg/mL in plasma has been associated with target engagement. The extent to which patients could be overexposed with the standard 1200 mg q3w dosing remains unknown. Here, we monitored atezolizumab peak and trough levels in 27 real‐world patients with lung cancer as part of routine therapeutic drug monitoring. Individual pharmacokinetic (PK) parameters were calculated using a population approach and optimal dosing‐intervals were simulated with respect to the target trough levels. No patient had plasma levels below 6 μg/mL. The results showed that the mean trough level after the first treatment was 78.3 ± 17 μg/mL, that is, 13 times above the target concentration. The overall response rate was 55.5%. Low‐grade immune‐related adverse events was observed in 37% of patients. No relationship was found between exposure metrics of atezolizumab (i.e., minimum plasma concentration, maximum plasma concentration, and area under the curve) and pharmacodynamic end points (i.e., efficacy and toxicity). Further simulations suggest that the dosing interval could be extended from 21 days to 49 up to 136 days (mean: 85.7 days, i.e., q12w), while ensuring plasma levels still above the 6 μg/mL target threshold. This observational, real‐world study suggests that the standard 1200 mg q3w fixed‐dose regimen of atezolizumab results in significant overexposure in all the patients. This was not associated with increased side effects. As plasma levels largely exceed pharmacologically active concentrations, interindividual variability in PK parameters did not impact efficacy. Our data suggest that dosing intervals could be markedly extended with respect to the target threshold associated with efficacy.

Domaines

Sciences du Vivant [q-bio]

Joseph Ciccolini : Connectez-vous pour contacter le contributeur

https://hal.science/hal-04352276

Soumis le : mardi 19 décembre 2023-08:19:29

Dernière modification le : vendredi 29 décembre 2023-08:06:45

Dates et versions

hal-04352276 , version 1 (19-12-2023)

Identifiants

HAL Id : hal-04352276 , version 1
DOI : 10.1002/psp4.13063

Citer

Sophie Marolleau, Alice Mogenet, Clara Boeri, Mourad Hamimed, Joseph Ciccolini, et al.. Killing a fly with a sledgehammer: Atezolizumab exposure in real‐world lung cancer patients. CPT: Pharmacometrics and Systems Pharmacology, 2023, 12 (11), pp.1795-1803. ⟨10.1002/psp4.13063⟩. ⟨hal-04352276⟩

Exporter

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

CNRS INRIA UNIV-AMU INRIA2 CRCM

15 Consultations

0 Téléchargements